Evonik Extends Long-term Research & Development Partnership with Genedata

Share Article

Significant Expansion of Genedata Phylosopher® and Genedata Expressionist® at Evonik for Industrial Biotechnology R&D Processes

Genedata’s software is key for us to efficiently store, process and interpret the biological and bioprocess-related data generated at our R&D and global production sites

Genedata, a leading provider of advanced software solutions for industrial biotechnology R&D, today announced an extended partnership with Evonik, a leading life science, specialty chemicals and material science company. Evonik is expanding the application of its central computational infrastructure and has renewed licenses for the Genedata Phylosopher® research data management system and the Genedata Expressionist® cross-omics and molecular profiling system. Genedata systems are now used across biotechnology research and development processes in the fields of health and nutrition and consumer specialties at Evonik. Specific applications areas include: production strain optimization for feed, food and pharma amino acids and derivatives; process monitoring for fermentation-based production; and novel developments for care specialties.

Genedata’s software is key for us to efficiently store, process and interpret the biological and bioprocess-related data generated at our R&D and global production sites,” said Stephan Hans, head of Functional Cell Analysis Group, R&D Bioproducts at Evonik. “With Genedata’s data management solutions we are able to centrally manage all data related to our proprietary production strains and processes. Data integrity, accessibility and process support are the main reasons why Evonik decided to use Genedata systems in the first place, and why Evonik is now broadening their application spectrum.”

Transcriptomics and metabolomics have become essential technologies for guiding our strain development processes. The increasing data complexity and data volumes acquired in each strain and process development project is dramatic, which is why we need a stable and scalable computational solution,” noted Dr. Ralf Kelle, vice president of R&D Biotechnology at Evonik. “In addition, strain genotyping using next-generation sequencing technology has enabled us to systematically assess whole strain ancestries on a molecular level. Genedata’s tools pinpoint production-relevant mutations and evaluate their impact on genes, pathways and overall production phenotypes.”

"We are proud to have been able to broaden our relationship with Evonik, a major player in industrial biotechnology,” commented Dr. Othmar Pfannes, CEO of Genedata. “Our computational platform is tailored to support biotechnological research and development processes. The increasing demand for bio-based products and sustainable production processes is driving our continuous commitment to develop solutions for the white biotech market.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, and Genedata Expressionist® make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US. http://www.genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Allison Kurz

+41 61 511 8459
Email >

Jackie Thrasivoulos

+1 508 881 3109
Email >
Visit website